OptiBiotix Health PLC Consumer survey results of GoFigure products (0029J)
September 06 2016 - 1:00AM
UK Regulatory
TIDMOPTI
RNS Number : 0029J
OptiBiotix Health PLC
06 September 2016
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Consumer Survey of GoFigure(R) products
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol,
diabetes and skin care, announces the results of an independent
consumer survey of the GoFigure(R) products. These products, in the
form of meal replacement shakes and natural snack bars, contain
SlimBiome(R). This is OptiBiotix's patented formulation developed
by experts in nutrition using ingredients shown to reduce weight in
human studies. GoFigure(R) products are produced by OptiBiotix's
majority owned subsidiary, The Healthy Weight Loss Company.
The results of the survey showed:-
1. 100% of customers who used the products over a continued
period lost weight (average 1.2kg weight loss per week, based on
average reduction of 7-9 lbs over three weeks)
2. 100% of customers reported that using GoFigure(R) products
led them to reduce food intake (typically by eating smaller food
portions)
3. 93% of customers reported that using GoFigure products had led to reduced snacking
4. 83% of customers reported they felt less hungry when using the product
This consumer survey was carried out by contacting customers who
bought directly from the GoFigure website with a response rate of
24% (30 customers).
Stephen O'Hara, CEO of OptiBiotix, commented: "We are delighted
that this customer survey supports the science behind the SlimBiome
formulation with GoFigure(R) customers reporting reduced hunger,
less snacking and easier weight loss. This new approach to weight
loss contrasts with many competitor products which lack strong
scientific rationale and typically rely on customers' self-control
to restrict calories and as a consequence have a high failure rate.
These results show that the incorporation of SlimBiome(R) into food
products helps customers to manage their weight loss by reducing
food intake without food cravings. Hunger free dieting is now a
consumer option and we hope to see a wider range of products
containing this unique formulation to support consumer choice."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Contact via Walbrook below
Executive
Cairn Financial Advisers Tel: 020 7148 7900
LLP
Liam Murray
Hybridan LLP (Joint Broker) Tel: 0203 764 2341
Claire Louise Noyce
Peterhouse Corporate Finance Tel: 020 7469 0936
Ltd (Joint Broker)
Lucy Williams / Duncan
Vasey
Walbrook PR Ltd Tel: 020 7933 8780 or
optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUVVVRNBAKRAR
(END) Dow Jones Newswires
September 06, 2016 02:00 ET (06:00 GMT)